openPR Logo
Press release

Deadline on Dec. 14th coming up in Lawsuit for Investors in Reata Pharmaceuticals, Inc. (NASDAQ: RETA) shares

12-07-2020 09:38 PM CET | Associations & Organizations

Press release from: Shareholders Foundation

A Deadline is coming up on December 14, 2020 in the lawsuit for certain investors in Reata Pharmaceuticals, Inc. (NASDAQ: RETA).

A Deadline is coming up on December 14, 2020 in the lawsuit for certain investors in Reata Pharmaceuticals, Inc. (NASDAQ: RETA).

A deadline is coming up on December 14, 2020 in the lawsuit filed for certain investors of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) over alleged securities laws violations by Reata Pharmaceuticals, Inc.

Investors who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) have certain options and there are strict and short deadlines running. Deadline: December 14, 2020. NASDAQ: RETA stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Eastern District of Texas the plaintiff alleges on behalf of purchasers of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) common shares between October 15, 2019 and August 7, 2020, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between October 15, 2019 and August 7, 2020, the Defendants made false and/or misleading statements and/or failed to disclose that the MOXIe Part 2 study results were insufficient to support a single study marketing approval of omaveloxolone for the treatment of FA in the U.S. without additional evidence, that as a result, it was foreseeable that the FDA would not accept marketing approval of omaveloxolone for the treatment of FA in the U.S. based on the MOXIe Part 2 study results, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Deadline on Dec. 14th coming up in Lawsuit for Investors in Reata Pharmaceuticals, Inc. (NASDAQ: RETA) shares here

News-ID: 2204120 • Views: 371

More Releases from Shareholders Foundation

Investigation announced for Long-Term Investors in NextCure, Inc. (NASDAQ: NXTC)
An investigation on behalf of current long-term investors in shares of NextCure, Inc. (NASDAQ: NXTC) concerning potential breaches of fiduciary duties by certain directors and officers of NextCure, Inc. (NASDAQ: NXTC was announced. Investors who are current long term investors in NextCure, Inc. (NASDAQ: NXTC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current
Investigation announced for Investors in shares of Harbor Custom Development, In …
An investigation was announced over potential securities laws violations by Harbor Custom Development, Inc. in connection with certain financial statements. Investors who purchased shares of Harbor Custom Development, Inc. (NASDAQ: HCDI), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Harbor Custom Development, Inc. regarding its business, its prospects and
Investigation announced for long-term Investors in salesforce.com, inc. (NYSE: C …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at salesforce.com, inc. Investors who purchased shares of salesforce.com, inc. (NYSE: CRM) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain salesforce.com directors breached their fiduciary duties and caused damage to the company and its shareholders. San Francisco, CA based
Lawsuit filed for Investors in shares of SolarWinds Corporation (NYSE: SWI)
An investor, who purchased shares of SolarWinds Corporation (NYSE: SWI), filed a lawsuit over alleged violations of Federal Securities Laws by SolarWinds Corporation. Investors who purchased shares of SolarWinds Corporation (NYSE: SWI) have certain options and for certain investors are short and strict deadlines running. Deadline: March 5, 2021. NYSE: SWI investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. On December 13, 2020 it was reported

All 5 Releases


More Releases for Reata

Lawsuit filed for Investors in Reata Pharmaceuticals, Inc. (NASDAQ: RETA) shares
An investor, who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA), filed a lawsuit iover alleged violations of Federal Securities Laws by Reata Pharmaceuticals, Inc. Investors who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) have certain options and for certain investors are short and strict deadlines running. Deadline: December 14, 2020. NASDAQ: RETA investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. On August 10, 2020,
Investigation announced for Investors in Reata Pharmaceuticals, Inc. (NASDAQ: RE …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Reata Pharmaceuticals, Inc. Investors who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Reata Pharmaceuticals, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders. Plano,
Investigation announced for Investors in shares of Reata Pharmaceuticals, Inc. ( …
An investigation was announced concerning potential securities laws violations by Reata Pharmaceuticals, Inc. in connection with certain financial statements. Investors who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Reata Pharmaceuticals, Inc. regarding its business, its prospects and its operations were
Ataxia Therapeutics Pipeline Analysis 2018 | Reata Pharmaceuticals, Inc., Voyage …
Ataxia is a type of movement disorder characterized by lack of muscle control or coordination of voluntary movements. Some of the symptoms observed in the patients with ataxia are poor coordination, change in speech, difficulty in swallowing, and unsteady walk. Download the sample report @ https://www.pharmaproff.com/request-sample/1078 The disease causes include head injury; stroke; autoimmune diseases, such as sarcoidosis and multiple sclerosis; paraneoplastic syndromes; and viral infections. The disease is also found in
Diabetic Nephropathy market 2020 | Pfizer, Inc., Merck & Co., Inc., Sanofi, Reat …
Diabetic nephropathy is known as the most significant impediment occurring in the kidney glomerulus which render the patient morbid or even worse in majority of the cases. Characterized by macroalbuminuria, diabetic nephropathy is diagnosed when more than 300 milligrams of albumin are present in the urine in a day. The global market for diabetic nephropathy was valued at US$ 2,262.2 million in 2014. Registering a steady CAGR of 5.6%, the
Diabetic Nephropathy market 2020 | Novartis AG, Pfizer, Inc., Merck & Co., Inc., …
Diabetic nephropathy is known as the most significant impediment occurring in the kidney glomerulus which render the patient morbid or even worse in majority of the cases. Characterized by macroalbuminuria, diabetic nephropathy is diagnosed when more than 300 milligrams of albumin are present in the urine in a day. The global market for diabetic nephropathy was valued at US$ 2,262.2 million in 2014. Registering a steady CAGR of 5.6%, the